Literature DB >> 235292

Myocardial guanylate cyclase: properties of the enzyme and effects of cholinergic agonists in vitro.

L E Limbird, R J Lefkowitz.   

Abstract

The characteristics of myocardial guanylate cyclase (GTP pyrophosphatelyase, EC 4.6.1.2) were studied. Specific activity of the myocardial enzyme in five vertebrate species was guinea pig greater than man greater than cat greater than dog greater than rat. In the guinea pig, guanylate cyclase activity was uniformly distributed throughout the anatomical regions of the heart. The major portion of the enzyme activity was retrieved in the supernatant fraction after centrifugation at 12 000 times g. The Km for GTP was similar in supernatant (0.12 mM) and particulate (0.21 mM) preparations, although the Ka for Mn2+ in particulate preparations (0.3-0.6 mM) was less than that observed for guanylate cyclase in the supernatant fraction (0.8-2.0 mM). ATP competitively inhibited supernatant and particulate activity. Addition of 0.005-10.0 mM Ca2+ to assay incubations did not enhance guanylate cyclase activity. Suspension of 105 000 times g supernatant guanylate cyclase preparations with membrane lipids or phosphatidylserine stimulated activity 1.4-4.3 fold, whereas similar treatment of particulate preparations caused little alteration of enzyme activity. Addition of the cholinergic agonists acetylcholine, carbachol or methacholine (10-4-10-8 M) to homogenate, supernatant, particulate and disrupted tissue slice preparations in the presence of 0.0012-1.2 mM GTP, 0.3-10.0 mM Mn2+ and 0.005-10.0 mM Ca2+ or 0.0012-1.2 mM ATP did not stimulate guanylate cyclase activity. Similarly, further stimulation of guanylate cyclase activity was not elicited when enzyme-lipid suspensions were assayed in the presence of cholinergic agents.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 235292     DOI: 10.1016/0005-2744(75)90299-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Regulation of guanylate and adenylate cyclase activities by lysolecithin.

Authors:  W T Shier; J H Baldwin; M Nilsen-Hamilton; R T Hamilton; N M Thanassi
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

2.  Stimulation of human platelet guanylate cyclase by unsaturated fatty acid peroxides.

Authors:  H Hidaka; T Asano
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

3.  Regulation of synthesis of guanosine 3':5'-cyclic monophosphate in neuroblastoma cells.

Authors:  T Bartfai; X O Breakefield; P Greengard
Journal:  Biochem J       Date:  1978-10-15       Impact factor: 3.857

4.  Adenylate cyclase, guanylate cyclase and cyclic nucleotide phosphodiesterases of guinea-pig cardiac sarcolemma.

Authors:  P J St Louis; P V Sulakhe
Journal:  Biochem J       Date:  1976-09-15       Impact factor: 3.857

5.  Properties of particulate, membrane-associated and soluble guanylate cyclase from cardiac muscle, skeletal muscle, cerebral cortex and liver.

Authors:  S J Sulakhe; N L Leung; P V Sulakhe
Journal:  Biochem J       Date:  1976-09-01       Impact factor: 3.857

6.  Guanylate cyclase. Subcellular distribution in cardiac muscle, skeletal muscle, cerebral cortex and liver.

Authors:  P V Sulakhe; S J Sulakhe; N L Leung; P J St Louis; R A Hickie
Journal:  Biochem J       Date:  1976-09-01       Impact factor: 3.857

7.  Human monocyte killing of Staphylococcus aureus: modulation by agonists of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate.

Authors:  M S O'Dorisio; G R Vandenbark; A F LoBuglio
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.